BioCardia (NASDAQ:BCDA) Full Year 2023 Results

Key Financial Results

• Revenue: US$477.0k (down 65% from FY 2022).
• Net loss: US$11.6m (loss narrowed by 2.8% from FY 2022).
• US$0.55 loss per share (improved from US$0.67 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

BioCardia Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 32%. Earnings per share (EPS) also missed analyst estimates by 20%.

Looking ahead, revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 1.8% from a week ago.

Risk Analysis

You still need to take note of risks, for example - BioCardia has 8 warning signs (and 3 which are a bit concerning) we think you should know about.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.